FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.290,01 +204,21 (+0,54%) Nasdaq
15.957,94 +346,18 (+2,22%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,70 +0,13 (+0,16%) Bitcoin EUR
59.720,75 -745,90 (-1,23%)
Nicox S.A. (0RCQ.L)
- GlobeNewswire
Number of voting rights as of April 30, 2023
Nicox SA Société anonyme with a registered capital of € 50,156,698 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On May 3, 2023, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) As of April 30, 2023 Total number of shares composing the share capital 50,156,698Total
- GlobeNewswire
Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China
Press ReleaseNicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China Nicox’s partner, Ocumension Therapeutics, announced on April 26, 2023, that they had received Priority Review Status for the New Drug Application for ZERVIATE in ChinaAccelerates the ZERVIATE® approval and launch, which are expected in China in 2024 April 28, 2023 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an internati
